The aim of the article is to examine and present the fundamental feature required of experts of the European Medicines Agency, which is impartiality. The assessment of the fulfilment of this attribute will be presented on the basis of two judgments of the Court of Justice of the EU: the judgment of the Court of 14 March 2024 Debregeas et associés Pharma (D & A Pharma) v. European Commission and European Medicines Agency, case C-291/22 P and the judgment of the Court of 22 June 2023 Federal Republic of Germany v. Pharma Mar SA and European Commission and Republic of Estonia v. Pharma Mar SA and European Commission, joined cases C-6/21 P and C-16/21 P. The structure of the article consists of five parts. After a brief introduction, some tasks of the European Medicines Agency will be presented. This is necessary for a proper understanding of the main research problem of the article. Next, the two aforementioned judgments of the Court of Justice of the EU will be presented in turn, together with the accompanying factual situations of the cases, the parties’ claims and the Court’s assessment. They will be accompanied by a presentation of the Agency’s documents and activities aimed at ensuring the impartiality of the experts. The article ends with conclusions containing the author’s own assessment of the considerations carried out.